Anthony M. Nicasio - Concepedia

Author

Anthony M. Nicasio

Hartford Hospital

Also Known As

Anthony M Nicasio, Anthony M. Nicasio, Anthony Nicasio

Publications

935

Citations

H-Index

Concepts

All Affiliations

Hartford Hospital Hartford Financial Services (United States)Albany College of Pharmacy and Health Sciences Institute for Clinical Pharmacodynamics (United States)University of Connecticut

About

Anthony M. Nicasio is an author at Hartford Hospital specializing in medicine, antimicrobial pharmacokinetics, and drug resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	477
2	Health Sciences	3	3	137
3	Emergency Medicine	2	2	217
4	Critical Care Medicine	1	1	119
5	Epidemiology	1	1	59

Anthony M. Nicasio

Publications

752

Citations

H-Index

Page 1

	Year	Citations
Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia Anthony M. Nicasio, Robert E. Ariano, Sheryl Zelenitsky, Antimicrobial Agents and Chemotherapy NephrologyPopulation PharmacokineticsPhysiologically-based Pharmacokinetic ModelingCritical Care MedicineRenal Function	2009	119
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an <i>In Vitro</i> Infection Model Brian VanScoy, Rodrigo E. Mendes, Anthony M. Nicasio, Antimicrobial Agents and Chemotherapy	2013	105
Optimization of meropenem dosage in the critically ill population based on renal function Jared L. Crandon, Robert E. Ariano, Sheryl Zelenitsky, Intensive Care Medicine HypertensionHemodialysisRenal FunctionMedicineKidney Failure	2010	98
Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia Anthony M. Nicasio, Kathryn J. Eagye, David P. Nicolau, Journal of Critical Care Empiric Antibiotic ChoiceAntibioticsPharmacodynamic-based Clinical PathwayRespiratory InfectionCombination Therapy	2009	87
Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival Nathaniel J. Rhodes, Joseph L. Kuti, David P. Nicolau, Antimicrobial Agents and Chemotherapy Improved SurvivalLogistic AnalysisDrug ResistanceSurvival ThresholdsImputed Exposures	2015	59
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an <i>In Vitro</i> Infection Model Anthony M. Nicasio, Brian VanScoy, Rodrigo E. Mendes, Antimicrobial Agents and Chemotherapy	2016	54
In Vivo Pharmacodynamic Profile of Tigecycline against Phenotypically Diverse <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Isolates Anthony M. Nicasio, Jared L. Crandon, David P. Nicolau Antimicrobial Agents and Chemotherapy Vivo Pharmacodynamic ProfileKlebsiella PneumoniaeAntimicrobial ChemotherapyAntibiotic ResistancePharmacodynamic Modeling	2009	44
An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity Nathaniel J. Rhodes, Joseph L. Kuti, David P. Nicolau, Journal of Infection and Chemotherapy MedicineCerebrospinal FluidForensic ToxicologyToxicologyNeuroprotection	2015	36
Evaluation of Once-Daily Vancomycin against Methicillin-Resistant Staphylococcus aureus in a Hollow-Fiber Infection Model Anthony M. Nicasio, Jürgen B. Bulitta, Thomas P. Lodise, Antimicrobial Agents and Chemotherapy Vancomycin ConcentrationsAntimicrobial ChemotherapyPharmacodynamic ModelingTotal Vancomycin AreaDrug Resistance	2011	34
Bronchopulmonary Disposition of Micafungin in Healthy Adult Volunteers Anthony M. Nicasio, Pamela R. Tessier, David P. Nicolau, Antimicrobial Agents and Chemotherapy	2008	32

Page 1